The UK and US have secured a major bilateral deal that will maintain zero levies on British pharmaceutical exports being sold in the American market.
Agreement Details of the Accord
In exchange for the tariff guarantee, the UK has pledged to raise expenditure on pharmaceuticals through the National Health Service (NHS). This commitment secures that import taxes on these crucial products will remain at zero for a timeframe of the next three years.
This deal follows previous statements to dramatically increase tariffs on patented drug products, with increases floated reaching double the cost.
"This arrangement between the Britain bolsters the worldwide climate for new treatments and brings much-needed fairness to transatlantic pharmaceutical trade," an announcement said.
Trade Importance
Medicines are one of the UK's largest export categories to the United States, which is easily the largest market for large UK drugmakers.
Statistics reveal that in the 12 months prior to September, the UK shipped drugs totaling billions to the US. This amount represented 17.4% of all goods exports in that span.
"This guarantee secures work, stimulates capital expenditure and sets the stage for the UK to become a worldwide center for medical research," the Business and Trade Secretary stated.
Key British Pledges
The agreement includes several notable changes from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the affordability limit at which it judges new treatments to be unaffordable by twenty-five percent.
- Boosted Medicine Funding: There is a aim to double total NHS spending on treatments from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
- Rebate Cap: The sum manufacturers must refund to the NHS to stay within budget will be capped at fifteen percent. Previously, repayments topped twenty percent.
Broader Context
This agreement follows a ongoing tension between the drug companies and the British authorities over drug pricing and approval rates.
This friction were heightened by assertions that American customers were charged a premium for the equivalent treatments than consumers in the Britain and the EU.
Recently, several major drug company projects in the UK have been delayed or cancelled, while multi-billion-dollar funding commitments have been directed toward American operations.
One official publicly accepted that the NHS needed to spend more on medicines, noting that its spending on drugs had decreased as a share of its resources over the previous ten-year period.
